GTBP
Price
$2.79
Change
-$0.30 (-9.68%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
10.7M
VKTX
Price
$28.19
Change
+$0.47 (+1.70%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
3.11B
20 days until earnings call
Interact to see
Advertisement

GTBP vs VKTX

Header iconGTBP vs VKTX Comparison
Open Charts GTBP vs VKTXBanner chart's image
GT Biopharma
Price$2.79
Change-$0.30 (-9.68%)
VolumeN/A
Capitalization10.7M
Viking Therapeutics
Price$28.19
Change+$0.47 (+1.70%)
Volume$95.57K
Capitalization3.11B
GTBP vs VKTX Comparison Chart in %
Loading...
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GTBP vs. VKTX commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTBP is a Hold and VKTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (GTBP: $3.10 vs. VKTX: $27.72)
Brand notoriety: GTBP and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GTBP: 122% vs. VKTX: 114%
Market capitalization -- GTBP: $10.7M vs. VKTX: $3.11B
GTBP [@Biotechnology] is valued at $10.7M. VKTX’s [@Biotechnology] market capitalization is $3.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GTBP’s FA Score shows that 1 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • GTBP’s FA Score: 1 green, 4 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, GTBP is a better buy in the long-term than VKTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GTBP’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 5 bullish TA indicator(s).

  • GTBP’s TA Score: 4 bullish, 4 bearish.
  • VKTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VKTX is a better buy in the short-term than GTBP.

Price Growth

GTBP (@Biotechnology) experienced а -7.86% price change this week, while VKTX (@Biotechnology) price change was +2.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

GTBP is expected to report earnings on May 15, 2025.

VKTX is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($3.11B) has a higher market cap than GTBP($10.7M). GTBP YTD gains are higher at: 1.508 vs. VKTX (-31.113). GTBP has higher annual earnings (EBITDA): -12M vs. VKTX (-171.93M). VKTX has more cash in the bank: 852M vs. GTBP (2.37M). GTBP has less debt than VKTX: GTBP (0) vs VKTX (1M). GTBP (0) and VKTX (0) have equivalent revenues.
GTBPVKTXGTBP / VKTX
Capitalization10.7M3.11B0%
EBITDA-12M-171.93M7%
Gain YTD1.508-31.113-5%
P/E RatioN/AN/A-
Revenue00-
Total Cash2.37M852M0%
Total Debt01M-
FUNDAMENTALS RATINGS
GTBP vs VKTX: Fundamental Ratings
GTBP
VKTX
OUTLOOK RATING
1..100
2563
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
10091
PRICE GROWTH RATING
1..100
3864
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GTBP's Valuation (33) in the null industry is in the same range as VKTX (40) in the Biotechnology industry. This means that GTBP’s stock grew similarly to VKTX’s over the last 12 months.

VKTX's Profit vs Risk Rating (75) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that VKTX’s stock grew similarly to GTBP’s over the last 12 months.

VKTX's SMR Rating (91) in the Biotechnology industry is in the same range as GTBP (100) in the null industry. This means that VKTX’s stock grew similarly to GTBP’s over the last 12 months.

GTBP's Price Growth Rating (38) in the null industry is in the same range as VKTX (64) in the Biotechnology industry. This means that GTBP’s stock grew similarly to VKTX’s over the last 12 months.

GTBP's P/E Growth Rating (100) in the null industry is in the same range as VKTX (100) in the Biotechnology industry. This means that GTBP’s stock grew similarly to VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GTBPVKTX
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
GTBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CUK26.831.32
+5.17%
Carnival PLC
PETZ1.030.04
+4.16%
TDH Holdings
FCBC41.000.56
+1.38%
First Community Bankshares
ELTX7.820.10
+1.23%
Elicio Therapeutics
UEC6.620.07
+1.07%
Uranium Energy Corp